These data indicate that, although a germline deletion of CYP2A7 may protect against initiation of ovarian cancer in the context of a BRCA1 germline pathogenic variant, somatic deletions of CYP2A7 may be important for the ovarian cancer development or progression. This evidence concerns the gene CYP2A7 and ovarian cancer.